Weekly research roundup
GLP-1 and muscle research: July 5-11, 2026
This week's papers span comparative drug efficacy, consensus nutrition guidance, and body-composition methodology relevant to GLP-1-assisted weight loss. A major BMJ network meta-analysis and a Lancet Diabetes & Endocrinology consensus statement both address lean-mass preservation directly, making them high-priority reads for this audience.
How to read this
- This roundup is compiled automatically from the abstracts of newly published research and is a neutral summary, not medical advice, not peer review, and not an endorsement. Studies vary in quality and preprints are not yet peer-reviewed. Read the linked source and talk to your clinician before changing anything.
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
This large systematic review and network meta-analysis in the BMJ analyzed 262 randomized controlled trials (99,791 participants) comparing 19 weight-loss drugs. At one year, tirzepatide produced the greatest weight loss (mean −14.9% vs. lifestyle modification) among agents with moderate-to-high certainty evidence. Critically for this audience, tirzepatide also reduced fat mass the most (by 25.7%) but reduced lean mass the most as well (by 8.3%). Subcutaneous semaglutide was the only drug associated with reduced all-cause mortality and myocardial infarction risk.
Why it matters: The head-to-head lean-mass loss data across multiple GLP-1 and obesity drugs is directly actionable information for readers trying to understand the body-composition trade-offs of different medications.
Nutritional, functional, and psychological considerations for incretin-based therapies in adults-an EASO, EFAD, and ECPO Consensus Statement.
This EASO-EFAD-ECPO Consensus Statement in The Lancet Diabetes & Endocrinology synthesizes evidence on nutritional, functional, and psychological considerations during incretin-based therapy (GLP-1 and dual GLP-1/GIP receptor agonists). It specifically addresses protein targets during weight loss, dietary quality, and mitigation of gastrointestinal side effects, and discusses pragmatic approaches—including adequate protein intake and progressive resistance exercise—that may support preservation of fat-free mass and physical function. The statement also calls for future longitudinal research on macronutrient requirements, musculoskeletal outcomes, and post-cessation maintenance.
Why it matters: This is one of the most directly relevant consensus documents available for muscle-on-GLP-1 readers, explicitly covering protein, resistance exercise, and fat-free mass preservation during incretin therapy.
Glucagon-Like Peptide-1 Receptor Agonist-Based Agents and Body Composition: Filling More Gaps.
This updated narrative review in Obesity examined body-composition changes with GLP-1 receptor agonist-based agents using DXA-based data from 40 reports. The authors found a mean fat-free mass loss of 29.1% (SD 19.0%) of total weight lost, which they note is in the upper range of expected fat-free mass loss compared with other non-surgical obesity interventions. The review highlights that functional measures of strength and performance, as well as body-composition data for newer GLP-1-based agents, remain important gaps—particularly for high-risk populations.
Why it matters: The quantification of fat-free mass loss as a proportion of total weight lost across GLP-1 studies is core information for readers concerned about muscle preservation.
Special Considerations When Using GLP-1 Receptor Agonists in the Treatment of Obesity and Diabetes Mellitus Type 2 in Older Adults.
This narrative review (published in Advances in Therapy) examines special considerations for using GLP-1 receptor agonists—including semaglutide, tirzepatide, and liraglutide—in older adults with obesity and type 2 diabetes. The authors note that sarcopenia is a particularly relevant concern in this age group and that weight-loss efforts with GLP-1 RAs require cautious approaches. They also highlight polypharmacy and side-effect burden as additional factors to weigh. The authors conclude that evidence in older adults specifically remains limited despite large trials supporting GLP-1 RAs more broadly.
Why it matters: Older adults on GLP-1 medications face heightened sarcopenia risk, making this review directly relevant to readers focused on preserving muscle during weight loss.
Turn the evidence into a plan
The MuscleOnGLP handbook
These studies point the same direction our guides already put into practice: resistance training and enough protein preserve muscle while you lose weight. The 30-page handbook is the full, cited protocol.
See the handbook — $5 →